Joined February 2016
- Tweets 23
- Following 32
- Followers 790
- Likes 14
6 Photos and videos
21 Oct 2025
The DFCI EGFR Center’s annual patient and caregiver forum is next month. Register to attend through the link below - we hope you can join us!
REGISTER NOW for the Chen-Huang Center's Fifth Annual Patient & Caregiver Forum, which will take place on Monday, November 17, 2025 from 6-8pm ET on Zoom and is FREE: tinyurl.com/2025egfrforum
E-mail EGFRcenter@dfci.harvard.edu with any questions!
#lungcancer #EGFR #LCAM
#FlorezLab
17
2,020
Julia Rotow MD retweeted
19 Oct 2025
IDEO Xchange: Phase III HARMONi‑6 shows ivonescimab chemo outperformed tislelizumab chemo in first‑line squamous NSCLC, with superior PFS and comparable safety. How practice‑changing do you consider these results?
19%
Practice changing – SOC
56%
Promising – needs OS
23%
Interesting - still early
2%
Limited impact
48 votes • Final results
5
5
1,280
Julia Rotow MD retweeted
19 Oct 2025
IDEO Xchange: Given the FLAURA2 exploratory analysis showing that osimertinib plus chemo improved OS across all major poor-prognosis subgroups, how likely are you to use the combination therapy as standard first-line treatment in these populations?
71%
Highly likely
20%
Somewhat likely
9%
Neutral
0%
Unlikely
35 votes • Final results
5
7
1,121
Julia Rotow MD retweeted
19 Oct 2025
IDEO Xchange: Based on results from BEAMION-1 LUNG-2 cohort 2, which showed a 77% objective response rate and 96% disease control rate in untreated HER2-mutated NSCLC, how likely are you to recommend zongertinib as initial therapy over standard chemotherapy for these patients?
74%
Very likely
15%
Somewhat likely
3%
Neutral
9%
Not likely
34 votes • Final results
2
7
7
1,398
18 Aug 2025
Join me on August 18 & 19 to hear inspiring stories from Dana-Farber patients and donate to strike out cancer: jimmyfund.gives/guest #KCANCER @TheJimmyFund
Sharing progress in personalized treatment for #lungcancer @DFarberThoracic @DFEGFRcenter
3
19
1,468
29 May 2025
Follow us at the DFCI EGFR Center for updates on emerging data from #ASCO25
@DFEGFRcenter #NSCLC #EGFR
OptiTROP-Lung03: sac-TMT
NeoADAURA: neoadj osi/chemo
HERTHENA-Lung02: HER3-DXd vs doublet
Temab-A MET ADC
SACHI: osi/savolitinib MET
Zipalertinib and BAY2927088 EGFR ex20ins
1
5
18
2,265
29 May 2025
#ASCO25 is here! Join me Monday at 8:30 AM at the Arie Crown Theater to explore the role of plasma-guided adaptive first-line chemoimmunotherapy for NSCLC, abstract #8515 bit.ly/3Hc6pXn
5
882
25 May 2022
I am excited to announce I will be presenting at PER’s NSCLC satellite symposium during #ASCO22 in Chicago. Join us for dinner at 6:30 pm CT and then an in-depth, expert review of NSCLC treatments and clinical trials. Register now: bit.ly/3rRKJoz #LCSM #NSCLC
8
22 Feb 2022
Kicking off #TTLC22 with a discussion of EGFR-mutant NSCLC. Great to see and discuss all the advances in the last year.
12
4 Jun 2021
A9 We are on the way to making #lungcancer a chronic disease - seeing gains in long-term survivability and more advances to come #AskReuters #ASCO2021
2
7
4 Jun 2021
A8 @DeboraBruno (abstract 9005 #ASCO21) describes lower rates of NGS testing and clinical trial enrollment among African American versus Caucasian patients, highlighting reduced access to many of the advances that we celebrate at the annual meeting #AskReuters
4
4 Jun 2021
A7 Progress at ASCO is always inspiring. Advances in targeted therapies, immunotherapies, and early diagnosis have helped to improve 5-year survival rates for NSCLC, up by 13% in the last five years. #AskReuters #ASCO2021
1
4
4 Jun 2021
A6 Progress in #EGFR exon 20ins NSCLC – a subset lacking targeted therapy options until recently. Now FDA approval of amivantamab and emerging data for exon 20 inhibitors like DZD9008, with a response rate of 48% reported by James Yang at #ASCO2021 (Abstract 9008) #AskReuters
2
6
4 Jun 2021
Exactly this - many gains to be made by effective implementation of existing advances in screening and personalized treatment for all patients. #AskReuters #ASCO2021
4 Jun 2021
#AskReuters#ASCO2021 We underutilize CT screening. Only 1 in 8 Americans who are eligible, get potentially life saving screening.
1
4
4 Jun 2021
Q3 We need to bring visibility to the ‘invisible disease’ through awareness and funding campaigns. It is also important to note that up to 50% of lung cancer occurs in those who have already quit smoking and in young patients >25% will be never smokers #AskReuters #ASCO21
2
1
2
4 Jun 2021
Q3 We see the stigma in society’s attitudes towards this diagnosis and in a paucity of public and private funding compared to other common cancer diagnoses. Though lung cancer is the #1 cause of cancer mortality, funding lags that of other diseases #AskReuters
3
4
4 Jun 2021
A2 Lung cancer screening reduces risk of dying from lung cancer, so those with a current or former history of tobacco should discuss with their doctors whether screening is right for them. This AHRQ decision aid effectivehealthcare.ahrq.gov… can help with that discussion #AskReuters
1
1
3 Jun 2021
4
3 Jun 2021
2 Jun 2021
#ASCO21 we are ready to go!💨
Here, some of the most interesting abstract on #LungCancer #LCSM that will be presented, very soon!
Take a look at that & enjoy 👁🗨
1
6